Inhibition of HIV activation in latently infected cells by flavonoid compounds

被引:136
作者
Critchfield, JW
Butera, ST
Folks, TM
机构
[1] Retrovirus Diseases Branch, Disease Control/Prevention Centers, Atlanta, GA 30333
关键词
D O I
10.1089/aid.1996.12.39
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 [免疫学];
摘要
Acute HIV-1 infection of H9 and C8166 cultures has been shown to be suppressed by certain flavonoids, and evidence for inhibition of HIV-1 protease, integrase, and reverse transcriptase by flavonoids also exists, The present aim was to determine whether flavonoids inhibit HIV-1 activation in models of latent infection, By screening flavonoids from six different classes, three structurally related compounds (chrysin, acacetin, and apigenin) were identified that inhibited HIV expression in TNF-alpha-treated OM-10.1 cultures, The three compounds had favorable potencies against HIV activation in relation to their growth inhibitory effects (therapeutic index 5-10), Chrysin also inhibited HIV expression in response to PMA in OM-10.1 cells, in ACH-2 cells stimulated with either TNF-alpha or PMA, and in 8E5 cultures, Furthermore, return to viral latency in OM-10.1 cells previously exposed to TNF-alpha occurred over a shorter time interval when chrysin was added, The inhibition of HIV activation was not dependent on preincubation with flavonoids relative to TNF, and was characterized by a lack of HIV RNA accumulation by Northern analysis, Gel-shift experiments revealed that NF-kappa B activation after TNF-alpha treatment was not inhibited by these agents, suggesting that some other critical factor(s) needed for viral transcription was being affected, These findings indicate that flavonoids inhibit HIV-1 activation via a novel mechanism, and that these agents are potential candidates for therapeutic strategies aimed at maintaining a cellular state of HIV-1 latency.
引用
收藏
页码:39 / 46
页数:8
相关论文
共 27 条
[1]
BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141
[2]
FLAVONOIDS - BIOCHEMICAL EFFECTS AND THERAPEUTIC APPLICATIONS [J].
BRANDI, ML .
BONE AND MINERAL, 1992, 19 :S3-S14
[3]
BRINKWORTH RI, 1992, BIOCHEM BIOPH RES CO, V2, P631
[4]
APPLICATION OF LATENT HIV-1 INFECTED CELLULAR-MODELS TO THERAPEUTIC INTERVENTION [J].
BUTERA, ST ;
FOLKS, TM .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 1992, 8 (06) :991-995
[5]
BUTERA ST, 1993, J IMMUNOL, V150, P625
[6]
OSCILLATION OF THE HUMAN-IMMUNODEFICIENCY-VIRUS SURFACE-RECEPTOR IS REGULATED BY THE STATE OF VIRAL ACTIVATION IN A CD4+ CELL MODEL OF CHRONIC INFECTION [J].
BUTERA, ST ;
PEREZ, VL ;
WU, BY ;
NABEL, GJ ;
FOLKS, TM .
JOURNAL OF VIROLOGY, 1991, 65 (09) :4645-4653
[7]
CHINNADURAI G, 1991, GENE, V101, P165, DOI 10.1016/0378-1119(91)90407-3
[8]
THE HIV-1 PROTEASE AS A THERAPEUTIC TARGET FOR AIDS [J].
DEBOUCK, C .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 1992, 8 (02) :153-164
[9]
PREVENTION OF ACTIVATION OF HIV-1 BY ANTIVIRAL AGENTS IN OM-10.1 CELLS [J].
FEORINO, PM ;
BUTERA, ST ;
FOLKS, TM ;
SCHINAZI, RF .
ANTIVIRAL CHEMISTRY & CHEMOTHERAPY, 1993, 4 (01) :55-63
[10]
FEORINO PM, 1993, 11 INT C AIDS BERL